Literature DB >> 23458854

The application of SPECT/CT for preoperative planning in patients with secondary hyperparathyroidism.

Lishi Zhen1, Huan Li, Xiaojian Liu, Benjamin H Ge, Jue Yan, Jigang Yang.   

Abstract

BACKGROUND AND
PURPOSE: Secondary hyperparathyroidism (SHPT) is a frequent and challenging issue in patients undergoing dialysis for chronic kidney disease. Surgical intervention in the form of parathyroidectomy is generally considered only in cases of severe SHPT. However, identification of the exact location of the parathyroid glands (PTGs) before parathyroidectomy is a challenge. The aim of this study was to evaluate the role of 99mTc sestamibi single-photon emission computed tomography (SPECT)/computed tomography (CT) in the detection of parathyroids to guide operative therapy in patients with SHPT. PATIENTS AND METHODS: Ninety patients with SHPT who were on hemodialysis were evaluated preoperatively with double-phase 99mTc sestamibi static planar and SPECT/CT parathyroid scintigraphy to evaluate for parathyroids before parathyroidectomy. The sensitivity, specificity, and accuracy of 99mTc sestamibi static planar and SPECT/CT scintigraphy were determined.
RESULTS: Compared with static planar scintigraphy, 99mTc sestamibi SPECT/CT was able to detect a larger number of PTGs per study, as well as PTGs of smaller diameter and PTGs of smaller size. The sensitivity, specificity, and accuracy of 99mTc sestamibi SPECT/CT in detecting PTGs were 78.9, 100, and 78.9%, respectively, compared with 55.6, 100, and 55.6% for static planar 99mTc sestamibi.
CONCLUSION: Our study indicates that 99mTc sestamibi SPECT/CT has a higher sensitivity compared with static planar scintigraphy in the preoperative evaluation of hemodialysis patients with SHPT because of chronic kidney disease. SPECT/CT can not only detect a larger number of PTGs but can also depict the precise location of PTGs more accurately when compared with static planar scintigraphy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23458854     DOI: 10.1097/MNM.0b013e32835f9447

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

3.  Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions.

Authors:  Zeynep Gozde Ozkan; Seher Nilgun Unal; Serkan Kuyumcu; Yasemin Sanli; Mehmet Fatih Gecer; Beyza Ozcinar; Yasemin Senyurek Giles; Yesim Erbil
Journal:  Indian J Surg       Date:  2016-05-04       Impact factor: 0.656

4.  Diagnosis performance of 99mTc-MIBI and multimodality imaging for hyperparathyroidism.

Authors:  Jun Zhou; Di-Yu Lu; Liang Xia; Xiao-Jie Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

5.  Utility of surgeon-performed pre-operative ultrasound in the localisation of parathyroid adenomas.

Authors:  Paul Rs Thomas; Andrew D Beggs; Thang S Han
Journal:  JRSM Cardiovasc Dis       Date:  2019-06-19

6.  Pre-operative Localisation of the Parathyroid Glands in Secondary Hyperparathyroidism: A Retrospective Cohort Study.

Authors:  Takahisa Hiramitsu; Toshihide Tomosugi; Manabu Okada; Kenta Futamura; Makoto Tsujita; Norihiko Goto; Shunji Narumi; Yoshihiko Watarai; Yoshihiro Tominaga; Toshihiro Ichimori
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

Review 7.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.